BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, today announced its President and CEO Pam Contag , Ph.D., will participate in Biotech Showcase Digital being held January 11-15, 2021 .
|
MOUNTAIN VIEW, Calif., Dec. 22, 2020 /PRNewswire/ -- BioEclipse Therapeutics, Inc (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, today announced its President and CEO Pam Contag, Ph.D., will participate in Biotech Showcase Digital being held January 11-15, 2021.
Details of the event are as follows:
During Biotech Showcase Digital, registered conference participants will be able to watch a pre-recorded presentation by BioEclipse. Also, Dr. Contag will host virtual one-on-one meetings with registered investors and pharmaceutical and biotechnology companies via the conference’s networking and scheduling platform, partneringONE®, to discuss BioEclipse’s business and highlight recent corporate achievements, as well as anticipated milestones in the clinical program for CRX100. BioEclipse has initiated an open-label, Phase 1 dose-escalation study to evaluate the safety, tolerability, and pharmacokinetic (PK) properties of CRX100 in advanced solid tumors that do not respond to standard of care, including triple-negative breast cancer, colorectal cancer, hepatocellular carcinoma, osteosarcoma, epithelial ovarian cancer, and gastric cancer. Meetings can be arranged through the Biotech Showcase 2021 website or by contacting either BioEclipse or Miriam Miller at Tiberend Strategic Advisors. BioEclipse is focused on the treatment of recurring cancers with a unique multi-mechanistic approach that could address cancers believed to be untreatable. Developed with technology exclusively licensed from Stanford University, CRX100 combines activated immune cells, known as cytokine-induced killer (CIK) cells, with a tumor-killing virus. As stand-alone therapies, these two agents have previously been assessed in human studies. When combined to create CRX100, the CIK cells protect the oncolytic virus and deliver it to cancer cells throughout the body. The two components then work together to attack primary tumors and metastatic disease. Data from preclinical studies shows that this combination approach also can trigger a long-lasting immune response that protects against relapse and disease recurrence. About BioEclipse Therapeutics™ Contacts:
SOURCE BioEclipse Therapeutics |
View original content to download multimedia:
